Insider Trading Alert - SMRT, FII And ALXN Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, Dec. 19, 2014, 71 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $119.85 to $228,846,700.60.

Highlighted Stocks Traded by Insiders:

Stein Mart (SMRT) - FREE Research Report

Williams John H Jr, who is Vice Chairman at Stein Mart, sold 33,654 shares at $14.70 on Dec. 19, 2014. Following this transaction, the Vice Chairman owned 111,700 shares meaning that the stake was reduced by 23.15% with the 33,654-share transaction.

The shares most recently traded at $14.54, down $0.16, or 1.13% since the insider transaction. Historical insider transactions for Stein Mart go as follows:

  • 4-Week # shares sold: 66,346
  • 12-Week # shares sold: 66,346
  • 24-Week # shares sold: 66,346

The average volume for Stein Mart has been 90,000 shares per day over the past 30 days. Stein Mart has a market cap of $664.7 million and is part of the services sector and retail industry. Shares are up 10.26% year-to-date as of the close of trading on Thursday.

Stein Mart, Inc. operates as an apparel retailer in the United States. It offers fashion apparel for women and men, as well as accessories, shoes, and home fashions. The company primarily focuses on 35-55 year old woman. As of November 1, 2014, it operated 268 stores. The stock currently has a dividend yield of 2.03%. The company has a P/E ratio of 30.2. Currently, there is 1 analyst who rates Stein Mart a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on SMRT - FREE

TheStreet Quant Ratings rates Stein Mart as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, good cash flow from operations, largely solid financial position with reasonable debt levels by most measures and increase in stock price during the past year. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Stein Mart Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Federated Investors (FII) - FREE Research Report

Bouda Brian P, who is Chief Compliance Officer at Federated Investors, sold 3,235 shares at $32.69 on Dec. 19, 2014. Following this transaction, the Chief Compliance Officer owned 30,366 shares meaning that the stake was reduced by 9.63% with the 3,235-share transaction.

The shares most recently traded at $32.82, up $0.13, or 0.4% since the insider transaction. Historical insider transactions for Federated Investors go as follows:

  • 4-Week # shares sold: 16,891
  • 12-Week # shares sold: 16,891
  • 24-Week # shares sold: 48,601

The average volume for Federated Investors has been 560,600 shares per day over the past 30 days. Federated Investors has a market cap of $3.4 billion and is part of the financial sector and financial services industry. Shares are up 13.85% year-to-date as of the close of trading on Thursday.

Federated Investors, Inc. is a publicly owned asset management holding company. The stock currently has a dividend yield of 3.12%. The company has a P/E ratio of 22.3. Currently, there are 2 analysts who rate Federated Investors a buy, 3 analysts rate it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on FII - FREE

TheStreet Quant Ratings rates Federated Investors as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, notable return on equity and solid stock price performance. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Federated Investors Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Alexion Pharmaceuticals (ALXN) - FREE Research Report

Sinha Vikas, who is Evp & Cfo at Alexion Pharmaceuticals, sold 5,493 shares at $182.08 on Dec. 19, 2014. Following this transaction, the Evp & Cfo owned 157,277 shares meaning that the stake was reduced by 3.37% with the 5,493-share transaction.

The shares most recently traded at $189.53, up $7.45, or 3.93% since the insider transaction. Historical insider transactions for Alexion Pharmaceuticals go as follows:

  • 4-Week # shares bought: 500
  • 4-Week # shares sold: 9,805
  • 12-Week # shares bought: 510
  • 12-Week # shares sold: 15,375
  • 24-Week # shares bought: 510
  • 24-Week # shares sold: 103,920

The average volume for Alexion Pharmaceuticals has been 1.2 million shares per day over the past 30 days. Alexion Pharmaceuticals has a market cap of $36.1 billion and is part of the health care sector and drugs industry. Shares are up 37.02% year-to-date as of the close of trading on Thursday.

Alexion Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes life-transforming therapeutic products. The company has a P/E ratio of 75.9. Currently, there are 13 analysts who rate Alexion Pharmaceuticals a buy, no analysts rate it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on ALXN - FREE

TheStreet Quant Ratings rates Alexion Pharmaceuticals as a buy. The company's strengths can be seen in multiple areas, such as its compelling growth in net income, robust revenue growth, largely solid financial position with reasonable debt levels by most measures, expanding profit margins and good cash flow from operations. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. Get the full Alexion Pharmaceuticals Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

null

More from Markets

P&G, GE and IBM Need to Innovate; Has Starbucks' Stock Grown Ice Cold?--ICYMI

P&G, GE and IBM Need to Innovate; Has Starbucks' Stock Grown Ice Cold?--ICYMI

Is Best Buy Sleeping With the Enemy With Amazon Partnership?

Is Best Buy Sleeping With the Enemy With Amazon Partnership?

Sprint, T-Mobile Might Have to Do More Than Make Promises to Get Deal Approved

Sprint, T-Mobile Might Have to Do More Than Make Promises to Get Deal Approved

Video: The S&P 500 Is Failing to Make New Highs

Video: The S&P 500 Is Failing to Make New Highs

Dow, S&P 500 and Nasdaq Finish Lower as Apple, P&G Slump

Dow, S&P 500 and Nasdaq Finish Lower as Apple, P&G Slump